Zobrazeno 1 - 10
of 306
pro vyhledávání: '"Hendrik-Tobias Arkenau"'
Autor:
Agostina Stradella, Melissa Johnson, Sanjay Goel, Haeseong Park, Nehal Lakhani, Hendrik‐Tobias Arkenau, Matthew D. Galsky, Emiliano Calvo, Vicente Baz, Victor Moreno, Omar Saavedra, Stephen J. Luen, Song Mu, Qiting Wan, Victoria Chang, Wa Zhang, Minal Barve
Publikováno v:
Cancer Medicine, Vol 13, Iss 13, Pp n/a-n/a (2024)
Abstract Background Pamiparib is a potent, selective, poly (ADP‐ribose) polymerase 1/2 inhibitor that demonstrates synthetic lethality in cells with breast cancer susceptibility gene mutations or other homologous recombination deficiency. This two
Externí odkaz:
https://doaj.org/article/cc5999ad6e9e49dc84848eaa5c506e2e
Autor:
Do-Youn Oh, Maria Alsina Maqueda, David I. Quinn, Peter J. O’Dwyer, Ian Chau, Sun Young Kim, Ignacio Duran, Daniel Castellano, Jordan Berlin, Begona Mellado, Stephen K. Williamson, Keun-Wook Lee, Francisca Marti, Paul Mathew, Muhammad Wasif Saif, Ding Wang, Elizabeth Chong, Jacqueline Hilger-Rolfe, James P. Dean, Hendrik-Tobias Arkenau
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background Ibrutinib, a first-in-class inhibitor of Bruton’s tyrosine kinase, is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. Based on encouraging preclinical data, safety and efficacy of
Externí odkaz:
https://doaj.org/article/1fe44534f0e94c6a89809b887b29866b
Publikováno v:
Cancers, Vol 16, Iss 1, p 31 (2023)
RET is a receptor tyrosine kinase that plays an important role in the development of neurons and kidneys. The gene encoding the rearranged-during-transfection (RET) receptor tyrosine kinase was first discovered in the 1980s. Activating RET mutations
Externí odkaz:
https://doaj.org/article/f1182409eb25418b84a193a69d70cdf0
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 7, Iss 1, Pp 1-18 (2022)
Abstract Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis. Most of the patients present with distant metastatic dis
Externí odkaz:
https://doaj.org/article/93579c822db24c2a96b4ee67b7791bd3
Autor:
Cristina Morelli, Vincenzo Formica, Paolo Bossi, Michela Rofei, Simona Guerriero, Silvia Riondino, Renato Argirò, Noemi Pucci, Tonia Cenci, Luca Savino, Carla G. Rinaldi, Francesco Garaci, Augusto Orlandi, Rolando M. D’Angelillo, Hendrik-Tobias Arkenau, Mario Roselli
Publikováno v:
Cancers, Vol 15, Iss 19, p 4716 (2023)
(1) Background: Sarcopenia lasting >1 year might be considered a chronic condition in many HNSCC patients. CT-scan-derived Skeletal Muscle Mass Index (SMI) is an established surrogate of sarcopenia; yet, the cut-off reported in the literature (litera
Externí odkaz:
https://doaj.org/article/a41b22031cf94ee8aeb89266cabe5faa
Autor:
Vincenzo Formica, Cristina Morelli, Veronica Conca, Maria Alessandra Calegari, Jessica Lucchetti, Emanuela Dell’Aquila, Marta Schirripa, Marco Messina, Lisa Salvatore, Federica Lo Prinzi, Giovanni Dima, Giovanni Trovato, Silvia Riondino, Mario Roselli, Ferdinandos Skoulidis, Hendrik-Tobias Arkenau, Chiara Cremolini
Publikováno v:
Cancers, Vol 15, Iss 11, p 3064 (2023)
Background: KRASG12C-mutated metastatic colorectal cancer (mCRC) has recently been recognized as a distinct druggable molecular entity; however, there are limited data on its sensitivity to standard chemotherapy. In the near future, the combination o
Externí odkaz:
https://doaj.org/article/a4d05e1ad76e4b3bb06ca44ed130ec1e
Autor:
Nataliya Mar, Yousef Zakharia, Alejandro Falcon, Rafael Morales-Barrera, Begona Mellado, Ignacio Duran, Do-Youn Oh, Stephen K. Williamson, Pablo Gajate, Hendrik-Tobias Arkenau, Robert J. Jones, Min Yuen Teo, Tolga Turan, Robert T. McLaughlin, Hillary M. Peltier, Elizabeth Chong, Harisha Atluri, James P. Dean, Daniel Castellano
Publikováno v:
Cancers, Vol 15, Iss 11, p 2978 (2023)
Ibrutinib is a first-in-class Bruton’s tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. We evaluated the safety and efficacy of ibrutinib, alone or combined with standard-of-
Externí odkaz:
https://doaj.org/article/3f71cdaeba5f4c0e924f34247590ed6e
Autor:
Hendrik-Tobias Arkenau, Emiliano Calvo, Alain Mita, Young Kwang Chae, Devalingam Mahalingam, Ugur Sahin, Elena Garralda, Oezlem Tuereci, Vladimir Galvao, Stefan Symeonides, Maria Miguel, Hariz Hassan, Annette Baumhauer, Timo Völker, Marie-Cristine Kühnle, Roman Rösemann, Stefan Strobl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/f934ebca1c46480bbd8a10a2221a40bb
Autor:
Hendrik-Tobias Arkenau, Marta Gil-Martin, Fiona Thistlethwaite, Karen A. Autio, Patrick A. Ott, Johanna Bendell, Patricia LoRusso, Valentina Boni, Alexander Spira, Javier Garcia-Corbacho, Mark Stroh, Elisabeth G.E. De Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Manreet Randhawa, Greg Durm, Alison L. Hannah
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background Probody® therapeutics are antibody prodrugs that are activated in the tumor microenvironment by tumor-associated proteases, thereby restricting the activity to the tumor microenvironment and minimizing ‘off-tumor’ toxicity. We report
Externí odkaz:
https://doaj.org/article/e9995b5c481945709e7709fd5db97be9
Autor:
Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do-Youn Oh, Lucjan Wyrwicz, Yoon-Koo Kang, Keun-Wook Lee, Jeffrey R. Infante, Sung Sook Lee, Margaret Kemeny, Ulrich Keilholz, Bohuslav Melichar, Alain Mita, Ruth Plummer, Denis Smith, Arnold B. Gelb, Huiling Xiong, Janet Hong, Vikram Chand, Howard Safran
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Abstract Background We evaluated the antitumor activity and safety of avelumab, a human anti–PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal cancer (GC
Externí odkaz:
https://doaj.org/article/22a26bd6feb14e4185d7a995dfe688b6